ArticleFrontiers in psychology2026
Development and psychometric validation of the short-form mandarin Chinese demoralization scale for cancer patients.
Article in Frontiers in psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Demoralization is a common psychological distress in Chinese cancer patients, affecting treatment adherence and quality of life. NCCN Guidelines recommend routine monitoring of distress. The original 24-item Mandarin Demoralization Scale (DS-MV) is comprehensive but less suited for rapid, repeated screening in busy oncology clinics. We therefore refined and validated a short-form Mandarin Demoralization Scale (s-DS-MV) for efficient demoralization assessment. Methods: This psychometric validation study initially enrolled 1,050 Chinese cancer patients between June 14, 2022 and June 13, 2023. Of these participants, 971 completed the original 24-item DS-MV through face-to-face questionnaire administration. Exploratory factor analysis and Rasch modeling were used to evaluate, refine, and revalidate the scale, including examinations of dimensionality, response scale appropriateness, item fit, item bias, and item difficulty. Test-retest reliability was assessed in a subgroup of 50 patients with relatively stable clinical symptoms. Results: The revised 14-item s-DS-MV (3-point Likert format) showed a 2-subscale structure supported by exploratory factor analysis. Rasch modeling confirmed acceptable model fit, unidimensionality and compliance with core criteria for each subscale. The scale exhibited satisfactory internal consistency and test-retest reliability (Existential Emptiness and Affective Distress subscale: 9 items, Conclusion: The s-DS-MV is a 3-point two-factor self-report scale with robust psychometric properties and favorable screening utility, making it well-suited for rapid clinical screening, dynamic monitoring, and related research on demoralization among cancer patients with similar demographic and clinical characteristics in Hunan and adjacent regions of China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.